# Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

> **NCT07285785** · PHASE4 · RECRUITING · sponsor: **Bausch Health Americas, Inc.** · enrollment: 54 (estimated)

## Conditions studied

- Diarrhea
- Gastroenteritis
- Bacterial Infection

## Interventions

- **DRUG:** Rifaximin 200 mg Tablet
- **OTHER:** Oral Rehydration Therapy (ORT)

## Key facts

- **NCT ID:** NCT07285785
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2027-04-20
- **Final completion:** 2027-07-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285785, "Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07285785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*